|
1
|
Goossens N and Hoshida Y: Hepatitis C
virus-induced hepatocellular carcinoma. Clin Mol Hepatol.
21:105–114. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of Cancer.
EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Llovet JM, Decaens T, Raoul JL, Boucher E,
Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, et al:
Brivanib in patients with advanced hepatocellular carcinoma who
were intolerant to sorafenib or for whom sorafenib failed: Results
from the randomized phase III BRISK-PS study. J Clin Oncol.
31:3509–3516. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pantel K and Alix-Panabieres C:
Circulating tumour cells in cancer patients: Challenges and
perspectives. Trends Mol Med. 16:398–406. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang W, Xia W, Lv Z, Ni C, Xin Y and Yang
L: Liquid biopsy for cancer: Circulating tumor cells, circulating
free DNA or exosomes? Cell Physiol Biochem. 41:755–768.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang J, Chang S, Li G and Sun Y:
Application of liquid biopsy in precision medicine: Opportunities
and challenges. Front Med. 11:522–527. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pinzani P, D'Argenio V, Del Re M,
Pellegrini C, Cucchiara F, Salvianti F and Galbiati S: Updates on
liquid biopsy: Current trends and future perspectives for clinical
application in solid tumors. Clin Chem Lab Med. 59:1181–1200.
2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qin X, Wang X, Liu F, Morris LE, Wang X,
Jiang B and Zhang Y: Gankyrin activates mTORC1 signaling by
accelerating TSC2 degradation in colorectal cancer. Cancer Lett.
376:83–94. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang C, Li X, Ren L, Ma C, Wu M, Liang W,
Zhao J, Li S, Tan Q, Liao Y, et al: Gankyrin as potential biomarker
for colorectal cancer with occult liver metastases. Front Oncol.
11(656852)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xu X, Lou Y, Tang J, Teng Y, Zhang Z, Yin
Y, Zhuo H and Tan Z: The long non-coding RNA Linc-GALH promotes
hepatocellular carcinoma metastasis via epigenetically regulating
Gankyrin. Cell Death Dis. 10(86)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Higashitsuji H, Itoh K, Nagao T, Dawson S,
Nonoguchi K, Kido T, Mayer RJ, Arii S and Fujita J: Reduced
stability of retinoblastoma protein by gankyrin, an oncogenic
ankyrin-repeat protein overexpressed in hepatomas. Nat Med.
6:96–99. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Jahangiri R, Mosaffa F, EmamiRazavi A,
Gharib M and Jamialahmadi K: Increased expression of gankyrin and
stemness factor oct-4 are associated with unfavorable clinical
outcomes and poor benefit of tamoxifen in breast carcinoma
patients. Pathol Oncol Res. 26:1921–1934. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Camacho-Moll ME, Macdonald J, Looijenga
LHJ, Rimmer MP, Donat R, Marwick JA, Shukla CJ, Carragher N,
Jørgensen A and Mitchell RT: The oncogene Gankyrin is expressed in
testicular cancer and contributes to cisplatin sensitivity in
embryonal carcinoma cells. BMC Cancer. 19(1124)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li H, Zhang J, Zhen C, Yang B and Feng L:
Gankyrin as a potential target for tumor therapy: evidence and
perspectives. Am J Transl Res. 10:1949–1960. 2018.PubMed/NCBI
|
|
16
|
Fu XY, Wang HY, Tan L, Liu SQ, Cao HF and
Wu MC: Overexpression of p28/gankyrin in human hepatocellular
carcinoma and its clinical significance. World J Gastroenterol.
8:638–643. 2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao X, Fu J, Xu A, Yu L, Zhu J, Dai R, Su
B, Luo T, Li N, Qin W, et al: Gankyrin drives malignant
transformation of chronic liver damage-mediated fibrosis via the
Rac1/JNK pathway. Cell Death Dis. 6(e1751)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Su B, Luo T, Zhu J, Fu J, Zhao X, Chen L,
Zhang H, Ren Y, Yu L, Yang X, et al:
Interleukin-1beta/Iinterleukin-1 receptor-associated kinase 1
inflammatory signaling contributes to persistent Gankyrin
activation during hepatocarcinogenesis. Hepatology. 61:585–597.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jing H, Zhang G, Meng L, Meng Q, Mo H and
Tai Y: Gradually elevated expression of Gankyrin during human
hepatocarcinogenesis and its clinicopathological significance. Sci
Rep. 4(5503)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Llovet JM, Chen Y, Wurmbach E, Roayaie S,
Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, et
al: A molecular signature to discriminate dysplastic nodules from
early hepatocellular carcinoma in HCV cirrhosis. Gastroenterol.
131:1758–1767. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang
W, Ren YB, Su B, Cao GW, Yang Y, et al: p28GANK overexpression
accelerates hepatocellular carcinoma invasiveness and metastasis
via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha
pathways. Hepatology. 53:181–192. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iwai A, Marusawa H, Kiuchi T, Higashitsuji
H, Tanaka K, Fujita J and Chiba T: Role of a novel oncogenic
protein, gankyrin, in hepatocyte proliferation. J Gastroenterol.
38:751–758. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chao J, Zhao S and Sun H:
Dedifferentiation of hepatocellular carcinoma: Molecular mechanisms
and therapeutic implications. Am J Transl Res. 12:2099–2109.
2020.PubMed/NCBI
|
|
24
|
Han J, Wang F, Lan Y, Wang J, Nie C, Liang
Y, Song R, Zheng T, Pan S, Pei T, et al: KIFC1 regulated by
miR-532-3p promotes epithelial-to-mesenchymal transition and
metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
Oncogene. 38:406–420. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang WP, Sun Y, Lu Q, Zhao JB, Wang XJ,
Chen Z, Ni YF, Wang JZ, Han Y, Zhang ZP, et al: Gankyrin promotes
epithelial-mesenchymal transition and metastasis in NSCLC through
forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling
pathway. Oncotarget. 8:5909–5923. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Oussalah A, Rischer S, Bensenane M, Conroy
G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T,
Reinicke D, Garcia M, et al: Plasma mSEPT9: A novel circulating
cell-free DNA-based epigenetic biomarker to diagnose hepatocellular
carcinoma. EBioMedicine. 30:138–147. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Qu C, Wang Y, Wang P, Chen K, Wang M, Zeng
H, Lu J, Song Q, Diplas BH, Tan D, et al: Detection of early-stage
hepatocellular carcinoma in asymptomatic HBsAg-seropositive
individuals by liquid biopsy. Proc Natl Acad Sci USA.
116:6308–6312. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu RH, Wei W, Krawczyk M, Wang W, Luo H,
Flagg K, Yi S, Shi W, Quan Q, Li K, et al: Circulating tumour DNA
methylation markers for diagnosis and prognosis of hepatocellular
carcinoma. Nat Mater. 16:1155–1161. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Kisiel JB, Dukek BA, Kanipakam RVS, Ghoz
HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K,
et al: Hepatocellular carcinoma detection by plasma methylated DNA:
Discovery, phase I pilot, and phase II clinical validation.
Hepatology. 69:1180–1192. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sohn W, Kim J, Kang SH, Yang SR, Cho JY,
Cho HC, Shim SG and Paik YH: Serum exosomal microRNAs as novel
biomarkers for hepatocellular carcinoma. Exp Mol Med.
47(e184)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
von Felden J, Schulze K, Krech T, wald F,
Nashan B, Pantel K, Lohse AW, Riethdorf S and Wege H: Circulating
tumor cells as liquid biomarker for high HCC recurrence risk after
curative liver resection. Oncotarget. 8:89978–89987.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu
SJ, Shi RY, Hu B, Zhou J and Fan J: Circulating stem cell-like
epithelial cell adhesion molecule-positive tumor cells indicate
poor prognosis of hepatocellular carcinoma after curative
resection. Hepatology. 57:1458–1468. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ogle LF, Orr JG, Willoughby CE, Hutton C,
McPherson S, Plummer R, Boddy AV, Curtin NJ, Jamieson D and Reeves
HL: Imagestream detection and characterisation of circulating
tumour cells-A liquid biopsy for hepatocellular carcinoma? J
Hepatol. 65:305–313. 2016.PubMed/NCBI View Article : Google Scholar
|
